These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 17919420

  • 1. [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
    Villavicencio C, Ramírez-Sarmiento A, Gayete A, Grau S, Orozco-Levi M.
    Arch Bronconeumol; 2007 Sep; 43(9):519-22. PubMed ID: 17919420
    [Abstract] [Full Text] [Related]

  • 2. [Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
    Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, Obrador-Lagares A, Genís-Batlle D, Sendra-Salillas S.
    Arch Bronconeumol; 2009 Feb; 45(2):100-2. PubMed ID: 19232272
    [Abstract] [Full Text] [Related]

  • 3. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E, Dom R, Demedts M.
    Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
    [Abstract] [Full Text] [Related]

  • 4. [Recurrent nerve paralysis and pleural effusion due to cabergoline].
    Muñoz-Morente A, Garcia-Trujillo L, Soto-Hurtado EJ, González-Benítez MA.
    Rev Neurol; 1992 Feb; 46(6):382-3. PubMed ID: 18368686
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
    McElvaney NG, Wilcox PG, Churg A, Fleetham JA.
    Arch Intern Med; 1988 Oct; 148(10):2231-6. PubMed ID: 3178380
    [Abstract] [Full Text] [Related]

  • 8. [Pleural effusion and severe edema of the lower limbs induced by bromocriptine].
    Messiaen T, Lefebvre C, Weynand B, Pieters T.
    Rev Med Interne; 1996 Oct; 17(8):680-3. PubMed ID: 8881198
    [Abstract] [Full Text] [Related]

  • 9. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Townsend M, MacIver DH.
    Heart; 2004 Aug; 90(8):e47. PubMed ID: 15253989
    [Abstract] [Full Text] [Related]

  • 10. Pleuropulmonary changes induced by ergoline drugs.
    Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, Debieuvre D, Bensa P, Piard F, Camus P.
    Eur Respir J; 1996 May; 9(5):1013-9. PubMed ID: 8793465
    [Abstract] [Full Text] [Related]

  • 11. [Constrictive pericarditis caused by carbergoline].
    Hjortshøj SP, Poulsen SH, Andreasen JJ.
    Ugeskr Laeger; 2006 Jun 26; 168(26-32):2572-3. PubMed ID: 16824416
    [Abstract] [Full Text] [Related]

  • 12. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
    Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F, Zelissen PM.
    Eur J Endocrinol; 2010 Apr 26; 162(4):667-75. PubMed ID: 20071478
    [Abstract] [Full Text] [Related]

  • 13. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Apr 26; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 14. Cabergoline-associated erythema nodosum.
    Kaushik P, Soule MR, Ellison WA, Ahmed B, Kaushik R.
    Ann Pharmacother; 2008 Feb 26; 42(2):284-7. PubMed ID: 18172015
    [Abstract] [Full Text] [Related]

  • 15. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Feb 26; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 16. [Pulmonary toxicity associated with cabergoline].
    Ozkurt H, Tufaner O, Gorgulu C.
    Arch Bronconeumol; 2009 Nov 26; 45(11):572-3. PubMed ID: 19523737
    [No Abstract] [Full Text] [Related]

  • 17. Low dose cabergoline induced interstitial pneumonitis.
    Frank W, Moritz R, Becke B, Pauli R.
    Eur Respir J; 1999 Oct 26; 14(4):968-70. PubMed ID: 10573251
    [Abstract] [Full Text] [Related]

  • 18. Pleuropulmonary disease associated with dopamine agonist therapy.
    Bhatt MH, Keenan SP, Fleetham JA, Calne DB.
    Ann Neurol; 1991 Oct 26; 30(4):613-6. PubMed ID: 1686385
    [Abstract] [Full Text] [Related]

  • 19. Mitral heart disease due to cabergoline.
    Martin M, Iglesias-Cubero G, Diaz Molina B, Moris De la Tassa C.
    Int J Cardiol; 2007 Jan 02; 114(1):e7-8. PubMed ID: 17052783
    [Abstract] [Full Text] [Related]

  • 20. Adverse drug reaction suggested by a clinical vignette.
    Finestone AJ.
    Clin Interv Aging; 2011 Jan 02; 6():199. PubMed ID: 21822375
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.